Overview
At a Glance
AOD-9604 is a modified fragment of human growth hormone (amino acids 177–191) that was developed specifically for fat loss without the other effects of full GH. Despite promising early animal data, it failed to outperform placebo in Phase 2 clinical trials for obesity. It's now marketed in some clinics and supplement-adjacent products, but the clinical evidence does not support meaningful weight-loss efficacy. It has TGA approval in Australia as a complementary medicine ingredient, which is sometimes misrepresented as proof of efficacy.
AOD-9604 (Advanced Obesity Drug 9604) is a synthetic peptide consisting of a modified fragment of human growth hormone (hGH). Specifically, it corresponds to amino acids 177–191 of hGH — the C-terminal region — with an added tyrosine residue at the N-terminus. This fragment was isolated and studied because it appeared to retain the lipolytic (fat-metabolizing) properties of full-length growth hormone while lacking the growth-promoting and diabetogenic effects that make hGH unsuitable as a weight-loss therapy (Ng et al., 2000).
The peptide was originally developed by Metabolic Pharmaceuticals Ltd., an Australian biotechnology company, in collaboration with Monash University researchers. The premise was straightforward: if the fat-burning portion of growth hormone could be separated from the portions that cause muscle growth, insulin resistance, and IGF-1 elevation, the result might be a targeted obesity treatment with fewer side effects than full hGH administration.
AOD-9604 showed promise in early preclinical studies, demonstrating lipolytic activity in cell culture and animal models without affecting blood glucose or IGF-1 levels (Ng & Borstein, 2000). However, the Phase 2B clinical trial for obesity did not meet its primary endpoint — treated subjects did not lose significantly more weight than placebo controls (Heffernan et al., 2001). This is a critical piece of the AOD-9604 story that is frequently omitted in marketing materials.
Despite the failed obesity trial, AOD-9604 has continued to circulate in the peptide therapy and anti-aging medicine space. It has also been explored for cartilage repair applications, receiving FDA Investigational New Drug (IND) approval for osteoarthritis research. It holds Generally Recognized as Safe (GRAS) status as a food additive, which is sometimes misrepresented as evidence of therapeutic approval.
Quick Facts
| Property | Details |
|---|---|
| Molecular formula | C₇₈H₁₂₃N₂₃O₂₃S₂ |
| Amino acid sequence | Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe |
| Molecular weight | ~1,817 Da |
| Parent molecule | Human growth hormone (hGH), amino acids 177–191 |
| Routes studied | Subcutaneous injection, oral |
| Human trials | Phase 2B obesity trial (did not meet primary endpoint) |
| FDA approval | None for therapeutic use; GRAS status as food additive only |
| WADA status | Prohibited |
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
How It Works
The mechanism of AOD-9604 is rooted in the observation that different regions of the growth hormone molecule are responsible for different biological activities. The C-terminal fragment (amino acids 177–191) appears to mediate fat metabolism, while other regions drive growth promotion and metabolic disruption.
Lipolysis Stimulation
AOD-9604 stimulates the breakdown of stored triglycerides in adipose (fat) tissue — a process called lipolysis. In cell culture studies using 3T3-L1 adipocytes (a standard fat cell model), AOD-9604 increased the release of glycerol, indicating enhanced triglyceride breakdown. This effect was comparable in magnitude to the lipolytic effect of full-length hGH (Ng & Borstein, 2000).
The lipolytic mechanism appears to involve activation of beta-3 adrenergic receptors on adipocytes, leading to increased cyclic AMP (cAMP) levels and activation of hormone-sensitive lipase (HSL), the enzyme responsible for cleaving stored triglycerides into free fatty acids and glycerol (Ng et al., 2000).
Lipogenesis Inhibition
In addition to breaking down existing fat, AOD-9604 appears to inhibit the formation of new fat (lipogenesis). Preclinical studies showed reduced incorporation of acetate into fatty acids in treated adipocytes, suggesting that the peptide suppresses de novo lipogenesis — the metabolic pathway by which the body converts excess carbohydrates into stored fat (Ng & Borstein, 2000).
Selective Activity: What AOD-9604 Does NOT Do
The defining feature of AOD-9604 is what it reportedly does not do. Unlike full-length hGH:
- No IGF-1 elevation: AOD-9604 did not increase circulating IGF-1 levels in animal or human studies. IGF-1 elevation is responsible for many of hGH's growth-promoting and potentially carcinogenic effects (Heffernan et al., 2001).
- No effect on blood glucose or insulin: Unlike full-length hGH — which promotes insulin resistance and can elevate blood sugar — AOD-9604 did not alter glucose homeostasis in preclinical or clinical studies.
- No anabolic (muscle-building) effects: The growth-promoting, muscle-building properties of hGH are mediated by different regions of the molecule.
- No effect on bone growth: AOD-9604 does not stimulate skeletal growth.
Cartilage-Related Mechanisms
More recently, AOD-9604 has been investigated for potential cartilage repair properties. Preclinical studies suggest the peptide may stimulate proteoglycan and collagen synthesis in chondrocytes (cartilage cells), possibly through upregulation of sulfated glycosaminoglycan production. This line of research led to an FDA IND approval for investigating AOD-9604 in osteoarthritis, though clinical results have not been widely published (Kwon et al., 2010).
Go Deeper
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Research
Preclinical Studies: Fat Metabolism
- In vitro lipolysis: AOD-9604 stimulated glycerol release (a marker of fat breakdown) in 3T3-L1 adipocytes at a magnitude comparable to full-length hGH. It also inhibited lipogenesis (new fat formation) in the same cell model (Ng & Borstein, 2000).
- Obese Zucker rats: Chronic administration of AOD-9604 reduced body weight gain in obese Zucker rats — a standard obesity model — without affecting food intake, blood glucose, or IGF-1 levels. The peptide appeared to selectively reduce adipose tissue mass (Ng et al., 2000).
- Obese mice (ob/ob): Similar weight-reducing effects were observed in genetically obese mice, with reduced fat pad weight and no alteration in lean body mass (Ng et al., 2000).
The Phase 2B Clinical Trial: A Critical Examination
This is the most important piece of clinical evidence for AOD-9604, and it produced a negative result.
Metabolic Pharmaceuticals conducted a Phase 2B, randomized, double-blind, placebo-controlled trial of oral AOD-9604 in obese adults. The study enrolled approximately 300 subjects and tested multiple dose levels of oral AOD-9604 over a 12-week treatment period (Heffernan et al., 2001).
Key findings:
- Primary endpoint not met: AOD-9604 did not produce statistically significant weight loss compared to placebo at any dose tested.
- No significant body composition changes: Fat mass reductions did not reach statistical significance versus placebo.
- Safety profile was favorable: No serious adverse events were attributed to AOD-9604. Blood glucose, insulin, and IGF-1 levels were not affected — confirming the selective mechanism seen in preclinical studies.
- The company discontinued obesity development: Following these results, Metabolic Pharmaceuticals pivoted away from AOD-9604 as an obesity drug.
The Phase 2B trial failure is frequently omitted from promotional materials about AOD-9604. Many vendors and clinics cite only the preclinical data (animal studies showing fat reduction) without disclosing that these results did not translate to human weight loss in the only controlled human trial conducted. This omission is misleading.
Cartilage Repair Research
- Chondrocyte studies: AOD-9604 stimulated proteoglycan synthesis in human chondrocyte cultures, suggesting potential for cartilage matrix repair. The effect was concentration-dependent (Kwon et al., 2010).
- Animal models: In a rabbit model of osteoarthritis, intra-articular administration of AOD-9604 showed reduced cartilage degeneration compared to vehicle controls.
- FDA IND status: AOD-9604 received Investigational New Drug (IND) clearance from the FDA for study as an osteoarthritis treatment (intra-articular injection). This allows clinical research to proceed but does not constitute approval or endorsement of efficacy.
- Clinical results pending: Comprehensive published results from controlled human osteoarthritis trials are not widely available in peer-reviewed literature.
GRAS Determination
AOD-9604 received Generally Recognized as Safe (GRAS) status from the FDA as a food additive. This determination:
- Means the substance is considered safe for consumption at food-additive levels
- Does NOT constitute therapeutic approval
- Does NOT indicate efficacy for any medical condition
- Is based on toxicological safety data, not clinical efficacy data
- Applies specifically to the food additive context, not pharmaceutical use
Limitations of the Research
- The only controlled human obesity trial failed. This is the most important data point and should not be dismissed.
- Preclinical promise did not translate to clinical efficacy. This is common in drug development — most compounds that work in animal models fail in humans.
- Cartilage research is early-stage. While the IND is promising, published controlled human data is limited.
- Limited independent replication: Much of the preclinical work was conducted by or funded by the same commercial entity (Metabolic Pharmaceuticals).
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Uses
FDA Status
AOD-9604 has no FDA-approved therapeutic indication. It holds GRAS status as a food additive only. It has an active IND for osteoarthritis research. Any therapeutic use is experimental.
How It Has Been Marketed and Used
| Application | Evidence Basis | Notes |
|---|---|---|
| Fat loss / body composition | Preclinical positive; Phase 2B negative | The most commonly marketed use. However, the only controlled human trial did not demonstrate significant weight loss. Preclinical lipolytic activity has not translated to measurable clinical fat loss. |
| Joint / cartilage support | Preclinical positive; clinical data limited | Emerging area with an active FDA IND. Preclinical data suggests chondroprotective effects. Intra-articular injection is the studied route for this application. |
| Anti-aging / metabolic health | Extrapolated from preclinical | Marketed in the anti-aging space based on its hGH-derived origin. No specific anti-aging clinical data exists for AOD-9604. |
| Sports recovery | Minimal evidence | Some athletes have used AOD-9604 for body composition optimization. It is prohibited by WADA. Evidence of sports performance benefit is absent. |
What AOD-9604 Is NOT Used For
- Muscle building: AOD-9604 does not have anabolic properties. It does not increase IGF-1 or promote muscle protein synthesis.
- Height or bone growth: The fragment does not retain the growth-promoting properties of full hGH.
- Diabetes treatment: While it does not worsen glucose homeostasis, it has no demonstrated glucose-lowering effects.
- Replacement for established obesity treatments: GLP-1 receptor agonists (semaglutide, tirzepatide) have robust Phase 3 data showing 15–25% body weight reduction. AOD-9604 failed to demonstrate any significant weight loss in its Phase 2B trial.
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Dosing
AOD-9604 is not FDA-approved. No official dosing guidelines exist. The information below reflects protocols commonly reported in clinical practice and research literature — it is provided for informational purposes only. Do not self-administer any peptide without guidance from a qualified healthcare provider. Dosing, preparation, and administration should be overseen by a licensed clinician.
Commonly Reported Protocols
| Route | Typical Dose | Frequency | Notes |
|---|---|---|---|
| Subcutaneous injection | 300–600 mcg | Once daily | Administered in the morning on an empty stomach. Abdominal subcutaneous injection is the most commonly reported site. |
| Oral formulation | Variable | Once daily | Oral AOD-9604 was used in the Phase 2B clinical trial. Bioavailability via the oral route is lower than subcutaneous injection. |
| Intra-articular (joint) | Research dosing | Varies | Under investigation for osteoarthritis. This route is used in clinical research settings only. |
Sources: Heffernan et al. (2001) — dosing in Phase 2B trial; Ng et al. (2000) — preclinical dosing ranges.
Cycling Patterns
- Common protocol: 8–12 weeks on, 4 weeks off
- Short course: 4–6 weeks for targeted body composition goals
- No established optimal duration: Cycling recommendations are based on clinical convention, not controlled evidence
Administration Guidance
AOD-9604 for subcutaneous use is typically supplied as a lyophilized powder requiring reconstitution. Preparation and administration should be demonstrated and supervised by your prescribing healthcare provider or pharmacist.
Storage
- Lyophilized powder: Store refrigerated (2–8°C / 36–46°F)
- Reconstituted solution: Refrigerate and use within 2–4 weeks
- Protect from light and heat
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Results: What Users Report
The following timeline is compiled from clinician reports, patient surveys, and online communities — not from randomized controlled trials. The Phase 2B clinical trial did not demonstrate significant weight loss. Individual experiences vary, and placebo effect cannot be excluded.
Reported Timeline
| Timepoint | What Users Typically Report |
|---|---|
| Week 1–2 | Most users report no noticeable changes. Some describe a subjective sense of increased energy or reduced appetite, which may reflect placebo effect. |
| Week 2–4 | Users who report positive effects describe modest reduction in abdominal fat, slight improvements in body composition, and reduced cravings. Changes are subtle. |
| Week 4–8 | Those who continue report incremental body composition changes. Weight loss, when reported, is typically 2–5 lbs over the full treatment period — which falls within the range of normal weight fluctuation and could be attributed to diet and exercise changes made concurrently. |
| Week 8–12 | Reports plateau. Users who combine AOD-9604 with caloric restriction and exercise report better results than those relying on the peptide alone — which itself suggests the peptide may not be the primary driver of changes. |
Interpreting User Reports
AOD-9604 user reports should be viewed with particular caution because:
- The controlled trial was negative. In a setting designed to isolate the peptide's effect from confounders, it did not work for weight loss.
- Concurrent lifestyle changes: Many users start AOD-9604 alongside new diet and exercise programs. The peptide gets credit for changes driven by behavior modification.
- Confirmation bias: After investing $100–$300/month, users are psychologically motivated to perceive improvement.
- Publication bias in communities: People who experience dramatic results post about them; those who notice nothing tend to remain silent.
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Side Effects
Reported Side Effects
| Side Effect | Frequency | Notes |
|---|---|---|
| Headache | Uncommon | Mild and transient. Reported in Phase 2 trial at rates similar to placebo. |
| Injection site reaction | Uncommon | Mild redness, swelling, or discomfort at subcutaneous injection site. Self-limiting. |
| Nausea | Uncommon | Mild and self-limiting. More common with oral formulation. |
| Dizziness | Rare | Transient, typically in first days of use. |
| Chest tightness | Rare | Reported infrequently in user communities. Causation not established. |
| Water retention | Rare | Mild and transient. Less than that seen with full hGH. |
What the Phase 2 Safety Data Showed
The Phase 2B clinical trial provided the most rigorous safety data available for AOD-9604. Key safety findings (Heffernan et al., 2001):
- No serious adverse events attributed to AOD-9604 at any dose level
- No changes in fasting blood glucose or insulin levels
- No elevation of IGF-1 (a key safety concern with hGH-derived compounds)
- No changes in complete blood count, liver function, or kidney function
- Adverse event rates were comparable between treatment and placebo groups
Theoretical Risks
- Long-term effects unknown: No long-term human safety data exists beyond the Phase 2 trial duration.
- Product quality variation: Research chemical sources may contain impurities or degradation products not present in pharmaceutical-grade preparations.
- Growth hormone fragment concerns: While AOD-9604 does not appear to share the metabolic side effects of full hGH, it is derived from the same molecule. Long-term monitoring data is absent.
Contraindications
- Pregnancy and breastfeeding — no safety data available
- Active cancer — as a precaution due to hGH-related origin, though AOD-9604 does not elevate IGF-1
- Children and adolescents — no pediatric data
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Regulatory Status
FDA Classification History
| Action | Status | Impact |
|---|---|---|
| Therapeutic approval | None | AOD-9604 has not been approved as a drug by the FDA for any indication. |
| GRAS status | Granted | Recognized as safe as a food additive. This applies to food-additive use only, not therapeutic use. Does not indicate efficacy for any medical condition. |
| IND for osteoarthritis | Active | FDA cleared AOD-9604 for clinical investigation as an intra-articular treatment for osteoarthritis. This permits research, not commercial sale. |
| Category 2 (2024) | Classified | FDA classified AOD-9604 as not suitable for compounding, restricting compounding pharmacy access. |
| Category 1 return | In progress | AOD-9604 is returning to Category 1, which would restore compounding pharmacy access. |
GRAS vs. FDA Approval: An Important Distinction
GRAS (Generally Recognized as Safe) status is frequently misrepresented in AOD-9604 marketing. Key clarifications:
- GRAS applies to food additives. It means the substance is considered safe for consumption at food-additive levels — similar to ingredients like caffeine or certain food colorings.
- GRAS does not mean "approved as a drug." It has no bearing on therapeutic efficacy or pharmaceutical-grade use.
- GRAS does not imply "safe at therapeutic doses." The safety assessment is for food-additive levels, which may be different from doses used in clinical applications.
- Vendor claims that AOD-9604 is "FDA approved" based on GRAS status are misleading.
WADA Prohibited Status
AOD-9604 is prohibited by WADA under multiple categories:
- S0 (Non-approved substances): Substances with no current regulatory approval for therapeutic use
- S2 (Peptide hormones, growth factors): As a growth hormone fragment, AOD-9604 falls under this category
- Prohibited at all times (in-competition and out-of-competition)
- Detection methods exist and are in active use
Notable Doping Cases
AOD-9604 gained public attention when it was linked to the Australian Football League (AFL) doping controversy involving the Essendon Football Club. Players were found to have been administered AOD-9604 as part of a broader supplements program, resulting in WADA sanctions.
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Cost
Typical Pricing
| Source | Typical Price Range | What You Get | Quality Assurance |
|---|---|---|---|
| Compounding pharmacy | $200–$300/month | Patient-specific preparation prescribed by a licensed provider. Lyophilized vial or oral capsules. | Highest — regulated pharmacy, USP standards, prescription required. |
| Research chemical supplier | $50–$150/month | Lyophilized powder vials labeled "for research only." | Variable — some provide COAs; quality varies widely. |
| Oral supplement | $100–$200/month | Oral capsules or lozenges, often combined with other ingredients. | Low to moderate — not regulated as drugs. |
Insurance Coverage
AOD-9604 is not covered by any insurance plan. All costs are out-of-pocket.
Cost-Effectiveness Consideration
Given that the only controlled human trial did not demonstrate significant weight loss, the cost-effectiveness of AOD-9604 for fat loss is questionable. For comparison:
| Treatment | Monthly Cost | Evidence for Weight Loss |
|---|---|---|
| AOD-9604 | $100–$300 | Phase 2B failed; no significant weight loss demonstrated |
| Semaglutide (Wegovy) | $300–$1,300 | Phase 3 trials: ~15% body weight loss |
| Tirzepatide (Zepbound) | $400–$1,100 | Phase 3 trials: ~20–25% body weight loss |
| Diet + exercise alone | $0–$100 | Well-established: 3–5% body weight loss typical |
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Questions & Answers
Myth: AOD-9604 is FDA approved for fat loss.
Answer: AOD-9604 has no FDA approval for any therapeutic indication. It has GRAS status as a food additive — this is not the same as drug approval. The Phase 2B trial for obesity failed to demonstrate significant weight loss (Heffernan et al., 2001). Claims of FDA approval are false.
Myth: AOD-9604 is proven to burn fat in humans.
Answer: AOD-9604 demonstrated lipolytic activity in cell culture and reduced fat accumulation in obese rodent models (Ng & Borstein, 2000). However, when tested in a controlled human trial, it did not produce statistically significant weight loss compared to placebo. Preclinical lipolytic activity did not translate to measurable human fat loss.
Myth: AOD-9604 is just like growth hormone but safer.
Answer: AOD-9604 is a fragment of growth hormone, not a complete analog. It correctly lacks the IGF-1-elevating and glucose-disrupting effects of full hGH. However, it also lacks the documented therapeutic effects of hGH. "Safer" is accurate in one narrow sense (no IGF-1/glucose effects), but the absence of demonstrated efficacy means there is no established benefit-to-risk ratio.
Myth: GRAS status means it's proven safe for therapeutic use.
Answer: GRAS status applies to food-additive levels of consumption and is based on toxicological safety data. It does not address safety at therapeutic doses, does not evaluate efficacy, and does not constitute pharmaceutical approval. Many common food ingredients have GRAS status — this does not make them medicines.
Myth: AOD-9604 has no side effects.
Answer: The Phase 2 trial data suggests a favorable safety profile with adverse event rates comparable to placebo. This is not the same as "no side effects." The trial was limited in duration and sample size, and long-term safety data does not exist. Side effects may exist that have not yet been characterized.
Myth: AOD-9604 is an alternative to GLP-1 medications.
Answer: This comparison is not supported by evidence. GLP-1 receptor agonists (semaglutide, tirzepatide) have demonstrated 15–25% body weight loss in large, Phase 3 controlled trials involving thousands of subjects. AOD-9604 failed to show significant weight loss in its only controlled human trial. These are not equivalent treatments by any evidence standard.
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Key Takeaways
Based on the available evidence:
- AOD-9604 is a modified fragment of human growth hormone (amino acids 177–191) that retains lipolytic activity in preclinical models without affecting IGF-1, blood glucose, or insulin sensitivity.
- The Phase 2B clinical trial for obesity failed. AOD-9604 did not produce statistically significant weight loss compared to placebo. This is the most important piece of clinical evidence and should inform any consideration of the peptide.
- Preclinical fat-loss results did not translate to humans. Despite positive animal and in vitro data, the peptide failed its clinical test. This is common in drug development but should not be minimized.
- Cartilage repair research is a more promising direction. The FDA IND for osteoarthritis suggests regulatory interest in this application, though comprehensive published clinical data is limited.
- The safety profile is favorable. Phase 2 data and preclinical toxicology indicate good tolerability with no serious adverse events, no IGF-1 elevation, and no glucose disruption.
- GRAS status is not therapeutic approval. Marketing claims that conflate food-additive safety recognition with pharmaceutical efficacy are misleading.
- It is returning to Category 1 after being placed in Category 2 in 2024, which would restore compounding pharmacy access.
- Cost ranges from $100–$300/month and is not covered by insurance.
Questions to Ask a Provider
- Are you aware that the Phase 2B obesity trial for AOD-9604 did not meet its primary endpoint?
- Given the lack of demonstrated efficacy for weight loss in humans, what is the rationale for prescribing it?
- Have you considered GLP-1 receptor agonists or other treatments with Phase 3 evidence?
- If recommending AOD-9604 for cartilage/joint support, what published clinical evidence supports this?
- Where will the product be sourced, and what quality testing has been performed?
- What monitoring is appropriate during treatment?
This content is for informational and educational purposes only. It is not intended as, and should not be interpreted as, medical advice. The information provided does not cover all possible uses, precautions, interactions, or adverse effects, and may not reflect the most recent medical research or guidelines. It should not be used as a substitute for the advice of a qualified healthcare professional. Never disregard professional medical advice or delay seeking treatment because of something you have read here. Always speak with your doctor or pharmacist before starting, stopping, or changing any prescribed medication or treatment. If you think you may have a medical emergency, call your doctor or emergency services immediately. GLPbase does not recommend or endorse any specific tests, physicians, products, procedures, or opinions. Use of this information is at your own risk.
Sources & Further Reading
Clinical Trials
Preclinical Research: Fat Metabolism
- Ng & Borstein (2000) — "The C-terminal fragment of hGH (AOD9604) stimulates lipolysis and inhibits lipogenesis" — Endocrinology
- Ng et al. (2000) — "Chronic treatment with AOD9604 reduces body fat in obese Zucker rats" — Obesity Research
Cartilage Research
Regulatory & Classification
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
